CIBC Private Wealth Group LLC Purchases 1,801 Shares of Illumina, Inc. (NASDAQ:ILMN)

CIBC Private Wealth Group LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the 4th quarter, Holdings Channel reports. The firm owned 165,305 shares of the life sciences company’s stock after buying an additional 1,801 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Illumina were worth $23,090,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Norges Bank bought a new stake in shares of Illumina during the 4th quarter worth approximately $228,714,000. WCM Investment Management LLC increased its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Pictet Asset Management Holding SA lifted its position in shares of Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock worth $158,011,000 after purchasing an additional 840,423 shares during the last quarter. ARK Investment Management LLC purchased a new stake in shares of Illumina during the fourth quarter valued at $91,714,000. Finally, Janus Henderson Group PLC grew its holdings in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 0.8 %

Illumina stock opened at $79.34 on Tuesday. The business has a fifty day moving average price of $101.65 and a 200-day moving average price of $126.49. Illumina, Inc. has a 1-year low of $77.54 and a 1-year high of $156.66. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of -10.33, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ILMN. Citigroup lowered their price objective on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada lowered their price target on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Finally, Robert W. Baird cut their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.